Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
All News
Article
Article
This week's Tuesday Nite Rheumatology featured Dr Jonathan Kay (U Mass) who gave an update on Biosimilars and took questions the subject. The program was moderated by Dr. Jack Cush.
Article
Today Eli Lilly announced that Taltz (ixekizumab) has received FDA approval for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA).
Dr Mariette summarizes the evidence for using cytokine-targeted therapies in #COVIDー19
Several studies with favorable results with #Tocilizumab and #Anakinra, however, almost all with methodological limitations (e.g., historical groups)
#EULAR2020 #EULAR20 #EULAR2020goesvirtual https://t.co/cMUKoeGfK9
MAINRITSAN3 RCT, RTX v PLBO in AAV
28mo relapse free survival ⬇️ RTX (96% vs 74%, NNT~4), majr (100% vs 87%, NNT~8)
1. Selected grp (all pts from MAINRITSAN2)
2. All pts had GC q3mos - IRL benefit could be bigger?
Strong data for RTX >2yrs in AAV
PDF: https://t.co/Mbrq7bFHk0 https://t.co/auKJ3QPKr0
Dr Philip Robinson
Tweet
Drug retention rates & treatment outcomes in 1,860 axSpA patients Rx with secukinumab in routine clinical practice in 13 European countries in the EuroSpA research collaboration network -> registry data drug retention rates THU0398 @RheumNow #EULAR2020 https://t.co/x3Y4tMetij https://t.co/DkUyIfyWwS
Dr Philip Robinson
Tweet
Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7
Dr Philip Robinson
Tweet
Integrated safety analysis of filgotinib treatment for RA from 7 clinical trials: 4,057 patients, VTE risk looks very reassuring #EULAR2020 @RheumNow https://t.co/Ld2tpu7UT5 https://t.co/sZqadeUTh8
Dr Philip Robinson
Tweet
Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%, data from the Phase III prevent trial Abstract OP0106 #EULAR2020 @rheumnow https://t.co/KATpGJs2y9 https://t.co/zeBFS2pMl0
#EULAR2020 OP0020: RABBIT 5500 pt study of all DMARDS/biologics, IL-6 inh may be the best to improve fatigue seen in RA patients @rheumnow https://t.co/VJW8MwMamM
#EULAR2020 Prof. T Domer: baricitinib show promise in phase II trial for SLE: Microarray analysis noted reduction in IFN signature; however, the reduction did not correlate w/SLEDAI-2K or SRI4 clinical response @RheumNow https://t.co/cW4egzSnAs
SELECT-PSA-2 results: UPA15 & UPA30 showed improvement across PsA domains vs PBO through Wk 24. No new safety signals were identified. Check out abstract #OP0223 for the MDA/ACR50/ACR70 responses. #EULAR2020 @RheumNow https://t.co/UAx2tkKSZI
IL-36 as a new biomarker/tx target in SpA? Check out this interesting in vitro study out of the UK and the IL-36 upstream induction of the IL-17/IL-23 pathway. #EULAR2020 @RheumNow #SAT0356 https://t.co/YTVepexd45
10 ReA pt study out of India reviewing ETN-b found that all pts (previously on ETN) responded to biosimilar med without new safety signals. Further details are here on abstract #AB0632 https://t.co/lRA2IDvU4H #EULAR2020 @RheumNow https://t.co/QyhwBzBBH3
David Liew
Tweet
Big one from plenary, new option in ANCA-associated vasculitis:
avacopan (anti-C5a) vs prednisolone in patients receiving CYC/RTX: non-inf at 26w, superior at 52w in the phase III ADVOCATE trial with reduction in steroid toxicity
Merkel, Jayne et al OP0011 #EULAR2020 @RheumNow
#eular2020 #op0302 Ianalumab (VAY736) dual action BAFFreceptor inhibitor/B cell depletion meets primary end point in p2b for pSS: EESDAI⬇️1.92 pts over PBO at wk24. Dis not meet 2ry endpoint ESSPRI&FACIT-F. Good side effect profile w/mild inj site reactions mostly @RheumNow https://t.co/9qsfUNho9h
David Liew
Tweet
Does TCZ actually fix GCA?
@nihrheumatology cohort w serial PET/CT q6m:
FDG uptake (PETVAS) reduces longitudinally over 2y but does not normalise, w rebound on TCZ cessation
Ongoing reductions in year 2? GCA doesn't sleep.
@KQuinnRheum @petercgrayson OP0144 #EULAR2020 @RheumNow https://t.co/aczQbONcNc
